

3 August 2015

2015/16 Invitation to Tender

PHARMAC is seeking feedback from medical groups, DHB hospital pharmacies and other interested parties on:

- A proposal to tender certain pharmaceuticals for sole supply; and
- The draft process and terms and conditions for the 2015/16 Invitation to Tender (2015/16 Tender).

PHARMAC welcomes all feedback on the 2015/16 Tender. Feedback received by the deadline may be considered by the Tender Medical Evaluation Subcommittee of PTAC, and would be considered by the PHARMAC Board (or its Delegate) prior to making a decision on this proposal.

ALL RESPONSES ARE DUE BY 5PM, THURSDAY 3 SEPTEMBER 2015

Feedback should be provided by submitting an email or letter to the Tender Analysts:

Email: tender@pharmac.govt.nz

Letter: Tender Analyst
PHARMAC
PO Box 10-254
Wellington 6143

DDI: Laurence Holding: (04) 901 2844
Chloe Dimock: (04) 916 7263

Feedback we receive is subject to the Official Information Act 1982 (OIA) and we will consider any request to have information withheld in accordance with our obligations under the OIA. Anyone providing feedback, whether on their own account or on behalf of an organisation, and whether in a personal or professional capacity, should be aware that the content of their feedback and their identity may need to be disclosed in response to an OIA request.

We are not able to treat any part of your feedback as confidential unless you specifically request that we do, and then only to the extent permissible under the OIA and other relevant laws and requirements. If you would like us to withhold any commercially sensitive, confidential proprietary, or personal information included in your submission, please clearly state this in your submission and identify the relevant sections of your submission that you would like it withheld. PHARMAC will give due consideration to any such request.

Details of the proposed 2015/16 Tender

In accordance with PHARMAC's objective (to secure, for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided), PHARMAC is consulting on a proposal to tender certain pharmaceuticals for Sole Subsidised Supply to community pharmacies and/or Hospital Supply Status for supply to DHB hospital pharmacies.

Attached to this letter (as Schedule Two) is a list of pharmaceuticals that we are considering tendering for Sole Subsidised Supply and/or Hospital Supply Status. Pharmaceuticals are sorted into therapeutic groups and then listed alphabetically in each group by chemical, form and strength. Each pharmaceutical has a 'C' and/or 'H' next to it to indicate whether it is proposed to be tendered for community and/or hospital supply.

In general, the proposed Tender process would be similar to the 2014/15 Tender. A copy of the draft 2015/16 Invitation to Tender is available on our website: www.pharmac.health.nz, or by contacting PHARMAC.

We are seeking feedback on the approach outlined in the following pages, in particular on:

- The proposed tender process and timeline;
- The actual or potential clinical implications of awarding Sole Subsidised Supply and/or Hospital Supply Status to the pharmaceuticals listed in Schedule Two, including the impact of a brand switch on patients and clinical staff; and
- For hospital pharmaceuticals, your views on the appropriate Discretionary Variance (DV) Limit for each pharmaceutical, in the event you consider a 1% DV Limit to be clinically unacceptable.

Background

Since 1997 PHARMAC has been using the strategy of tendering pharmaceuticals for sole supply of pharmaceuticals for a fixed period of time. Regular tendering has proven to be an effective way to encourage competition among suppliers of pharmaceuticals. As in the past, the community and hospital tender processes would be run in unison, however, the pharmaceutical list for community and hospital supply may be different.

Key Aspects of Awarding a Tender for Community Pharmaceuticals:

- For community pharmaceuticals, the tender winning brand would be the only subsidised brand for up to approximately 3 years. The Sole Subsidised Supply period would conclude on 30 June 2019 for all Tenders awarded from the 2015/16 Tender.
- No other brand of the pharmaceutical would be listed (or subsidised) in Section B of the Pharmaceutical Schedule during the Sole Subsidised Supply period.
- Other brands could continue to be marketed, sold and dispensed during the Sole Subsidised Supply Status period, but they would not receive a subsidy.
- Any pharmaceutical that currently carries a manufacturer's surcharge (that is, the additional patient charge above that of the patient co-payment) would become fully subsidised if a tender was awarded for that pharmaceutical.

Key Aspects of Awarding a Tender for DHB Hospital Pharmaceuticals:

- For DHB hospital pharmaceuticals, the Hospital Supply Status brand would be the only brand DHB Hospitals could purchase (subject to any allowance for alternative brands under the agreed DV Limits) for up to approximately 3 years. The Hospital Supply Status period would conclude on 30 June 2019 for all tenders awarded from the 2015/16 Tender.
- No other brand of the pharmaceutical would be listed in Section H of the Pharmaceutical Schedule during the Hospital Supply Status period.

Tender Timelines

The proposed timelines for the 2015/16 Tender are as follows:

Date	Event
3 August 2015	Consultation with suppliers, medical groups and interested parties on the proposed pharmaceutical list and draft Invitation to Tender.
27 August 2015	Final date for receipt of Alternative Commercial Proposals (ACPs) to tendering by PHARMAC.
3 September 2015	Final date for all consultation to be received.
September 2015	PHARMAC considers feedback from consultation, negotiates with suppliers over any ACP proposals it considers would meet PHARMAC's Decision Criteria and enters into provisional contracts with suppliers where appropriate.
September 2015	Meeting of the Tender Medical Evaluation Subcommittee of PTAC to consider clinical issues in relation to the proposed Tender list.
September/October 2015	Consultation and Board decisions on Alternative Commercial Proposals.
Early November 2015	Issuing of the 2015/16 Tender.
17 December 2015	Invitation to Tender closes.
From end of January 2016	Board decisions on the first Tender winners announced.

Contractual obligations for suppliers

A copy of the draft terms and conditions which would form the terms of the 2015/16 Tender contract is available on the PHARMAC website: www.pharmac.health.nz, or by phoning PHARMAC on 0800 66 00 50.

Proposed inclusion of the following provisions in the 2015/16 Invitation to Tender

Pharmaceutical Price

PHARMAC propose to include provisions in the 2015/16 Invitation to Tender that amend the terms and conditions relating to pharmaceutical price changes in the market.

In summary, PHARMAC propose to amend the price change date for a pharmaceutical that is currently listed and awarded a tender to the following:

- If the pharmaceutical is currently listed on the Schedule, then the price must change from the 12th of the month prior to the start date, and the supplier must provide price support to wholesalers (or other such distributors) to ensure pharmacy can purchase stock at the new price; or
- If the pharmaceutical is currently listed on the Schedule, then the supplier may reduce the price from the 1st of the month prior to the start date instead of price support to wholesalers (or other such distributors) provided there is more than 2 months lead time.

The incumbent supplier must note in its tender bid which of the above price change criteria would apply to its pharmaceutical. If there is no notification provided by a supplier then the price change on the 12th of the month prior to the start date with price support to wholesalers (or other such distributors) would be considered the default position.

If the pharmaceutical has a rebate, PHARMAC may at its option ask suppliers to reduce the price of the pharmaceutical on the 22nd of the month prior to the start date provided the supplier provides price support to wholesalers (or other such distributors) to ensure that pharmacy can purchase stock at the new price.

PHARMAC acknowledge that price support would require wholesalers (or other such distributors) to provide information on stockholding of a pharmaceutical to allow a supplier to provide price support which would include stock on hand of the pharmaceutical on the 12th of the month prior to the start date.

For pharmaceuticals that are not currently listed on the Schedule, the provisions stated in the terms and conditions of the draft 2015/16 Invitation to Tender will apply.

Unresolved Tender Bids

PHARMAC would review any unresolved Tender Bids from 2013/14 Tender and the 2014/15 Tender prior to issuing the 2015/16 Tender, and may close the tender for some of these items, and reissue them as part of the 2015/16 tender. The following Tender Bids remain unresolved, and may potentially be added to the 2015/16 Tender following consultation:

2013/14 Invitation to Tender

Chemical Name	Line Item
Aciclovir	Eye oint 3%
Ciprofloxacin	Eye Drops 0.3%
Hyoscine N-butylbromide	Tab 10 mg
Ornidazole	Tab 500 mg
Thiopental [Thiopentone] sodium	Inj 500 mg
Zinc	Crm BP
Zinc	Oint BP

2014/15 Invitation to Tender

Chemical Name	Line Item
Atorvastatin	Tab 10 mg
Atorvastatin	Tab 20 mg
Atorvastatin	Tab 40 mg
Atorvastatin	Tab 80 mg
Atropine sulphate	Inj 600 mcg, 1 ml
Baclofen	Inj 2 mg per ml, 5 ml
Bimatoprost	Eye Drops 0.03%
Bortezomib	Inj 3.5 mg
Brimonidine Tartrate with Timolol Maleate	Eye drops 0.2% with timolol maleate 0.5%
Buspirone hydrochloride	Tab 5 mg
Buspirone hydrochloride	Tab 10 mg
Calcipotriol	Crm 50 mcg per g (pack size 30 g or less)
Calcipotriol	Crm 50 mcg per g (pack size greater than 30 g)
Calcipotriol	Oint 50 mcg per g (pack size 30 g or less)
Calcipotriol	Oint 50 mcg per g (pack size greater than 30 g)
Candesartan with hydrochlorothiazide	Candesartan 8 mg, hydrochlorothiazide 12.5 mg tablet
Candesartan with hydrochlorothiazide	Candesartan 16 mg, hydrochlorothiazide 12.5 mg tablet
Caspofungin	Inj 50 mg
Caspofungin	Inj 70 mg

Chemical Name	Line Item
Celiprolol	Tab 200 mg
Chloramphenicol	Eye oint 1%
Chloramphenicol	Inj 1 g
Clonazepam	Tab 500 mcg
Clonazepam	Tab 2 mg
Clonidine	Inj 150 mcg per ml, 1 ml
Condoms	Latex-free 55 mm or greater (nominal width)
Crisantaspase	Inj 10,000
Dipyridamole	Tab long-acting 150 mg
Domperidone	Tab 10 mg
Eptifibatide	Inj 0.75 mg per ml, 100 ml
Eptifibatide	Inj 2 mg per ml, 10 ml
Famotidine	Tab 20 mg
Fludarabine phosphate	Inj 50 mg
Fondaparinux sodium	Inj 2.5 mg syringe
Granisetron	Inj 1 mg
Hyoscine N-butylbromide	Inj 20 mg, 1 ml
Ketamine	Inj 100 mg per ml, 2 ml vial
Latanoprost with timolol	Eye drops 50 mcg per ml with timolol 0.5%
Lidocaine [Lignocaine] Hydrochloride	Inj 1%, 5 ml
Lidocaine [Lignocaine] Hydrochloride	Inj 1%, 20 ml
Lidocaine [Lignocaine] Hydrochloride	Inj 2%, 5 ml

Chemical Name	Line Item
Lidocaine [Lignocaine] Hydrochloride	Inj 2%, 20 ml
Lidocaine [lignocaine] hydrochloride with adrenaline	Inj 2% with adrenaline 1:80,000, 2.2 ml dental cartridge
Metformin Hydrochloride	Tab immediate-release 1 g
Methadone hydrochloride	Inj 10 mg per ml, 1 ml
Midazolam	Inj 1 mg per ml, 5 ml
Midazolam	Inj 5 mg per ml, 3 ml
Milrinone	Inj 1 mg per ml, 10 ml
Mixed salt solution for eye irrigation	Eye irrigation solution calcium chloride 0.048% with magnesium chloride 0.03%, potassium chloride 0.075%, sodium acetate 0.39%, sodium chloride 0.64% and sodium acetate 0.17%, 15 ml
Mixed salt solution for eye irrigation	Eye irrigation solution calcium chloride 0.048% with magnesium chloride 0.03%, potassium chloride 0.075%, sodium acetate 0.39%, sodium chloride 0.64% and sodium acetate 0.17%, 250 ml
Mixed salt solution for eye irrigation	Eye irrigation solution calcium chloride 0.048% with magnesium chloride 0.03%, potassium chloride 0.075%, sodium acetate 0.39%, sodium chloride 0.64% and sodium acetate 0.17%, 500 ml
Naloxone Hydrochloride	Inj 400 mcg per ml, 1 ml
Nitrofurantoin	Tab 50 mg
Nitrofurantoin	Tab 100 mg

Chemical Name	Line Item
Nitrofurantoin	Tab modified release 50 mg
Nitrofurantoin	Tab modified release 100 mg
Oestradiol	TDDS 25 mcg per day
Oestradiol	TDDS 50 mcg per day
Oestradiol	TDDS 75 mcg per day
Oestradiol	TDDS 100 mcg per day
Oxycodone hydrochloride	Inj 10 mg per ml, 1 ml
Oxycodone hydrochloride	Inj 10 mg per ml, 2 ml
Oxycodone hydrochloride	Inj 50 mg per ml
Oxycodone hydrochloride	Tab controlled-release 5 mg
Oxycodone hydrochloride	Tab controlled-release 10 mg
Oxycodone hydrochloride	Tab controlled-release 20 mg
Oxycodone hydrochloride	Tab controlled-release 40 mg
Oxycodone hydrochloride	Tab controlled-release 80 mg
Propranolol	Cap long-acting 160 mg
Pyrazinamide	Tab 500 mg
Tobramycin	Inj 40 mg per ml, 2 ml
Travoprost with timolol	Eye drops 0.004% with timolol 0.5%
Trimethoprim with sulphamethoxazole [Co-trimoxazole]	Tab trimethoprim 80 mg and sulphamethoxazole 400 mg
Urokinase	Inj 10,000 iu
Urokinase	Inj 100,000 iu
Urokinase	Inj 500,000 iu

Should any unresolved Tender Bids be declined, PHARMAC would consider including those pharmaceuticals in the 2015/16 Tender. Currently unresolved Tender Bids have not been included in the draft pharmaceutical list set out in Schedule Two.

Distribution of Consultation Documents

Although this consultation letter has been widely distributed, should you consider that a particular person, group or agency should receive this letter and/or future tender documents, please feel free to contact PHARMAC or refer it on directly (note, all tender documents and consultations are also available from our website at www.pharmac.health.nz/news#consultation). We also invite any person or group to contact PHARMAC should you wish to meet to discuss the proposals contained in this consultation letter.

Schedule Two: Possible pharmaceuticals for tender for sole supply

Order of pharmaceuticals in this Schedule

Pharmaceuticals have been listed in groups according to the therapeutic group classification system used in the Pharmaceutical Schedule. Below is a list of these groups, and the corresponding page numbers for your ease of reference. Pharmaceuticals with indications that may apply to multiple therapeutic groups will only appear in one group.

<i>Therapeutic Group</i>	Page Numbers
Alimentary Tract and Metabolism	9
Blood and Blood Forming Organs	9 – 10
Cardiovascular System	10 – 13
Dermatologicals	13 – 15
Extemporaneously Compounded Preparations & Galenicals	15
Genito-Urinary System	15 – 16
Hormone Preparations – Systemic excluding contraceptives	16 – 17
Infections – Agents for Systemic Use	17 – 19
Musculoskeletal System	9 – 20
Nervous System	20 – 23
Oncology and Immunosuppressants	23 – 25
Respiratory System and Allergies	25 – 26
Sensory Organs	26 – 28

Information provided for each pharmaceutical

For each pharmaceutical (as defined by chemical name, form and strength) we have provided the following information:

- the current ex-manufacturer subsidy per unit of measure as at 1 July 2015
- the number of subsidised or partially subsidised units sold in the community in the year ending 30 June 2014
- an estimate of the annual community market value at current subsidies (estimated by multiplying the volume of units subsidised in the year ending 30 June 2014 by the relevant listed unit subsidy as at 1 July 2014); and
- comments specifically relating to the Tender of the line item and/or its current listing on the Pharmaceutical Schedule.

Explanation of terms, symbols and abbreviations

Most terms and abbreviations used are self-explanatory: “tab” means tablet, “cap” means capsule, “liq” means liquid, “inj” means injection, “suppos” means suppository, “grans” mean granules and “OP” means original pack to be dispensed.

The following table explains the symbols used in the draft pharmaceutical list:

Symbol	Explanation
Underlined	Pharmaceutical line items where a sole supply contract is in force are underlined. The price and subsidy for these pharmaceuticals are fixed until 30 June 2015 unless otherwise stated in the Comments column and a listing of a new brand could only occur after that date.
C	To be tendered for Sole Subsidised Supply Status (community pharmaceuticals).
H	To be tendered for Hospital Supply Status (DHB hospital pharmaceuticals).
PCT	A reference in the Invitation to Tender to allow Pharmaceuticals Cancer Treatments to be listed in Section B of the Pharmaceutical Schedule as part of PHARMAC’s Pharmaceutical Cancer Treatments project.
+	PHARMAC has been advised of the existence of a patent.
*	There is no fully funded product available for this line item (in relation to community supply).
@	Additional Stock Pharmaceuticals (ASP) means a Pharmaceutical, marked with an “@”, for which the supplier of the successful Tender Bid would be required to hold additional stock.
#	A rebate currently exists.

Changes to PHARMAC’s decision making mechanism

PHARMAC is changing the way it makes decisions. Currently, PHARMAC uses Decision Criteria to identify pharmaceuticals which best help it achieve PHARMAC’s Statutory Objective:

“to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment within the funding provided”

PHARMAC has made a decision to move away from the Decision Criteria to the Factors for Consideration. More information on the Factors for Consideration can be found on the PHARMAC website:

<http://www.pharmac.health.nz/medicines/how-medicines-are-funded/factors-for-consideration/>

The issues PHARMAC considers when it makes decisions is fundamental to PHARMAC’s work, so it’s important suppliers understand what the new Factors for Consideration are, and how the change is going to occur. PHARMAC has intentionally not specified a 'go live' date, in order to be confident of effective implementation. However, PHARMAC anticipates this change may mean that some decisions relating to the 2015/2016 Tender may be made under the Decision Criteria and others will be made under the Factors for Consideration.

At the time of the release of the draft 2015/2016 Tender, PHARMAC anticipates that further information will be available relating to the timing of the transition and the effect that this change may have on the 2015/2016 Tender and PHARMAC will keep suppliers informed in this respect.

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Alimentary Tract and Metabolism

Chemical Name						
Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments	
Ascorbic acid						
<u>Tab 100 mg</u>	3,550,190	\$49,703	\$0.0140	C H	1%	
Calcitriol						
Cap 0.25 mcg	1,591,475	\$160,739	\$0.1010	C H	1%	
Cap 0.5 mcg	497,303	\$93,154	\$0.1873	C H	1%	
Ferrous salts						
<u>Oral liq</u>	4,553,632	\$93,623	\$0.0206	C H	1%	
Glycerol						
Suppos 2.55 g				C H	1% Not currently listed in Section B of the Pharmaceutical Schedule	
Suppos 1.27 g				C H	1% Not currently listed in Section B of the Pharmaceutical Schedule	
Glycopyrronium bromide						
Inj 0.2 mg per ml, 1 ml				H	1%	
Ispaghula (psyllium) husk						
<u>powder/granules</u>	69,636,500	\$767,394	\$0.0110	C H	1% Units and unit subsidy expressed as 'per g'	
Lactulose						
<u>Oral liq 10 g per 15 ml</u>	209,592,551	\$1,609,671	\$0.0077	C H	1% Preference for 500-600 ml pack size.	
Loperamide hydrochloride						
<u>Cap 2 mg</u>	7,866,127	\$154,176	\$0.0196	C H	1%	
Tab 2 mg	2,064,878	\$46,212	\$0.0224	C H	1%	
Misoprostol						
Tab 200 mcg	56,279	\$26,695	\$0.4743	C H	1%	
Multivitamins						
<u>Tab (BPC cap strength)</u>	19,278,031	\$146,513	\$0.0076	C H	1%	
Omeprazole						
Inf 40 mg				H	1%	
Inj 40 mg	3,338	\$19,127	\$5.7300	C H	1%	
Pantoprazole						
<u>Tab EC 20 mg</u>	7,335,003	\$196,578	\$0.0268	C H	1%	
<u>Tab EC 40 mg</u>	9,933,428	\$351,643	\$0.0354	C H	1%	
Sodium citrate with sodium lauryl sulfoacetate						
<u>Enema 90 mg with sodium lauryl sulfoacetate 9 mg per ml, 5 ml</u>	403,964	\$161,182	\$0.3990	C H	1%	
Sulphasalazine						
<u>Tab 500 mg</u>	256,355	\$29,942	\$0.1168	C H	1%	
<u>Tab EC 500 mg</u>	6,463,727	\$833,174	\$0.1289	C H	1%	
Thymol glycerin						
Compound, BPC	229,455	\$4,199	\$0.0183	C H	1%	
Vitamin B complex (BPC, strong)						
<u>Tab</u>	3,066,137	\$26,369	\$0.0086	C H	1%	

Blood and Blood Forming Organs

Chemical Name						
Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments	
Alteplase						
Inj 10 mg				H	1%	
Inj 2 mg				H	1%	
Inj 50 mg				H	1%	
Aspirin						
Suppos 300 mg				H	1%	
<u>Tab 100 mg</u>	107,231,926	\$1,137,731	\$0.0106	C H	10%	
<u>Tab dispersible or soluble 300 mg</u>	1,578,319	\$40,247	\$0.0255	C H	1%	

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Blood and Blood Forming Organs

Chemical Name					DV	
Line Item	Units	Cost	Unit Subsidy		Limit	Comments
Clopidogrel						
<u>Tab 75 mg</u>	7,628,581	\$497,689	\$0.0652		C H 1%	
Compound electrolytes						
<u>Powder for soln for oral use</u>	974,002	\$175,320	\$0.1800		C H 1%	Units and unit subsidy expressed as 'per sachet'
Compound electrolytes with glucose [dextrose]						
<u>Soln with electrolytes</u>	104,725,000	\$685,949	\$0.0066		C H 1%	Units and unit subsidy expressed as 'per ml'
Filgrastim						
<u>Inj 300 mcg per ml, 0.5 ml prefilled syringe</u>	10,322	\$1,114,776	\$108.0000 #		C H 1%	There may be longer transition periods for this product. A confidential rebate currently exists. There would be a preference for sharps bins to be supplied
Inj 300 mcg per ml, 1 ml vial					H 1%	There may be longer transition periods for this product. There would be a preference for sharps bins to be supplied
<u>Inj 480 mcg per ml, 0.5 ml prefilled syringe</u>	2,261	\$390,701	\$172.8000 #		C H 1%	There may be longer transition periods for this product. A confidential rebate currently exists. There would be a preference for sharps bins to be supplied
Gemfibrozil						
<u>Tab 600 mg</u>	413,127	\$121,182	\$0.2933		C H 1%	
Potassium chloride						
Tab eff 548 mg (14 mmol) with chloride 285 mg (8 mmol)	293,144	\$25,700	\$0.0877 *		C H 1%	
Sodium chloride						
Inj 0.45%, bag					H 1%	
Inj 0.9%, 1,000 ml bag					H 1%	
Inj 0.9%, 100 ml bag					H 1%	
Inj 0.9%, 250 ml bag					H 1%	
Inj 0.9%, 50 ml bag					H 1%	
Inj 0.9%, 500 ml bag					H 1%	
Inj 1.8%, 500 ml bottle					H 1%	
Inj 3%, bag					H 1%	
Soln 0.9% for irrigation, 30 ml					H 1%	There may be a preference for plastic ampoules
Inj 0.9%, 5 ml	174,563	\$37,880	\$0.2170		C H 1%	There may be a preference for plastic ampoules
Inj 0.9%, 10 ml	532,482	\$122,471	\$0.2300		C H 1%	There may be a preference for plastic ampoules
Inj 0.9%, 20 ml	98,786	\$41,540	\$0.4205		C H 1%	There may be a preference for plastic ampoules
<u>Inj 23.4%, 20 ml</u>	1,759	\$10,994	\$6.2500		C H 1%	
Tranexamic acid						
<u>Tab 500 mg</u>	2,187,536	\$503,133	\$0.2300		C H 1%	
Water for injection						
Purified for inj, 250 ml bag					H 1%	
Purified for inj, 500 ml bag					H 1%	
Purified for injection, 1,000 ml bag					H 1%	
Purified for inj 5 ml	24,738	\$5,071	\$0.2050		C H 1%	There may be a preference for plastic ampoules
Purified for inj 10 ml	242,494	\$54,561	\$0.2250		C H 1%	There may be a preference for plastic ampoules
Purified for inj 20 ml	73,942	\$24,031	\$0.3250		C H 1%	There may be a preference for plastic ampoules

Cardiovascular System

Chemical Name					DV	
Line Item	Units	Cost	Unit Subsidy		Limit	Comments

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Cardiovascular System

Chemical Name						
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
Adenosine						
Inj 3 mg per ml, 10 ml					H 1%	
Inj 3 mg per ml, 2 ml					H 1%	
Adrenaline						
Inj 1 in 1,000, 1 ml	82,337	\$82,008	\$0.9960		C H 1%	
Inj 1 in 10,000, 10 ml	14,046	\$68,825	\$4.9000		C H 1%	
Ambrisentan						
Tab 10 mg	1,470	\$224,665	\$152.8333 #		C H 1%	A confidential rebate currently exists. Longer transition periods may apply to this product
Tab 5 mg	600	\$91,700	\$152.8333 #		C H 1%	A confidential rebate currently exists. Longer transition periods may apply to this product
Amiloride						
Tab 5 mg	37,194	\$6,509	\$0.1750		C H 1%	
Amiodarone hydrochloride						
<u>Inj 50 mg per ml, 3 ml</u>	8,773	\$33,337	\$3.8000		C H 1%	
Tab 100 mg	664,691	\$413,218	\$0.6217		C H 1%	
Tab 200 mg	910,361	\$926,138	\$1.0173		C H 1%	
Bumetanide						
Inj 500 mcg per ml, 4 ml			\$1.5900		C H 1%	
Tab 1 mg	1,694,521	\$277,224	\$0.1636		C H 1%	
Chlortalidone [chlorthalidone]						
Tab 25 mg	1,357,220	\$217,155	\$0.1600		C H 1%	
Cholestyramine						
Powder for oral liq 4 g	96,608	\$37,194	\$0.3850		C H 1%	Units and unit subsidy expressed as 'per sachet'
Cilazapril						
<u>Tab 0.5 mg - 1 mg</u>	19,251,815	\$427,775	\$0.0222		C H 1%	1 mg tablets must be scored. Units and unit subsidy shown are per 0.5 mg tablet
<u>Tab 2.5 mg</u>	21,566,340	\$1,032,812	\$0.0479		C H 1%	
<u>Tab 5 mg</u>	22,835,605	\$1,771,129	\$0.0776		C H 1%	
Cilazapril with hydrochlorothiazide						
<u>Tab 5 mg with hydrochlorothiazide 12.5 mg</u>	21,888,862	\$2,346,486	\$0.1072		C H 1%	
Clonidine						
Tab 150 mcg	565,319	\$194,017	\$0.3432		C H 1%	
Digoxin						
Inj 250 mcg per ml, 2 ml					H 1%	
Tab 250 mcg	1,403,116	\$84,888	\$0.0605		C H 1%	
Tab 62.5 mcg	9,938,614	\$276,194	\$0.0278		C H 1%	
Disopyramide Phosphate						
Cap 100 mg	37,872	\$5,681	\$0.1500		C H 1%	
Cap 150 mg	19,224	\$5,039	\$0.2621		C H 1%	
Esmolol						
Inj 10 mg per ml, 10 ml					H 1%	
Furosemide						
Inj 10 mg per ml, 25 ml	460	\$4,429	\$9.6280		C H 1%	
Inj 10 mg per ml, 2 ml	20,816	\$5,412	\$0.2600		C H 1%	
Glyceryl trinitrate						
Tab 500 mcg - 600 mcg	104,000	\$8,320	\$0.0800		C H 1%	Units and unit subsidy shown are per 600 mg tablet
Spray 400 mcg per dose	30,040,000	\$534,712	\$0.0178		C H 1%	
Inj 1 mg per ml, 5 ml					H 1%	
Inj 1 mg per ml, 50 ml					H 1%	
Inj 5 mg per ml, 10 ml					H 1%	

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Cardiovascular System

Chemical Name						
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
Hydralazine						
Tab 25 mg	11,616				C H 1%	
Inj 20 mg per ml, 1 ml	465	\$2,409	\$5.1800		C H 1%	
Iloprost						
Inj 100 mcg per ml, 0.5 ml					H 1%	
Indapamide						
Tab 2.5 mg	1,682,433	\$42,061	\$0.0250		C H 1%	
Isosorbide mononitrate						
Tab long-acting 40 mg	749,520	\$187,380	\$0.2500		C H 1%	Restriction on reference pricing until 30 June 2016
Tab long-acting 60 mg	9,644,663	\$422,243	\$0.0438		C H 1%	Restriction on reference pricing until 30 June 2016
Isradipine						
Cap long-acting 2.5 mg	54,891	\$13,723	\$0.2500		C H 1%	
Cap long-acting 5 mg	64,701	\$16,930	\$0.2617		C H 1%	
Labetalol						
Tab 50 mg	220,024	\$18,108	\$0.0823		C H 1%	
Tab 100 mg	736,141	\$74,056	\$0.1006		C H 1%	
Tab 200 mg	822,953	\$144,428	\$0.1755		C H 1%	
Levosimendan						
Inj 2.5 mg per ml, 10 ml vial					H 1%	
Inj 2.5 mg per ml, 5 ml vial					H 1%	
Methyldopa						
Tab 125 mg	98,465	\$14,031	\$0.1425		C H 1%	
Tab 250 mg	538,384	\$81,296	\$0.1510		C H 1%	
Tab 500 mg	121,749	\$28,185	\$0.2315		C H 1%	
Metolazone						
Tab 5 mg					H 1%	
Mexiletine						
Cap 150 mg	5,749	\$5,864	\$1.0200		C H 1%	
Cap 250 mg	27,860	\$18,109	\$0.6500		C H 1%	
Midodrine						
Tab 2.5 mg	224,394	\$118,929	\$0.5300		C H 1%	
Tab 5 mg	130,855	\$103,375	\$0.7900		C H 1%	
Minoxidil						
Tab 10 mg	13,331	\$9,331	\$0.7000		C H 1%	
Tab 2.5 mg					C H 1%	Not currently listed in the Pharmaceutical Schedule. Any listing may be subject to a Special Authority restriction
Tab 5 mg					C H 1%	Not currently listed in the Pharmaceutical Schedule. Any listing may be subject to a Special Authority restriction
Nicorandil						
Tab 10 mg	129,661	\$60,400	\$0.4658 #		C H 1%	A confidential rebate currently exists
Tab 20 mg	38,005	\$21,080	\$0.5547 #		C H 1%	A confidential rebate currently exists
Nimodipine						
Inj 0.2 mg per ml, 50 ml					H 1%	
Tab 30 mg					H 1%	
Noradrenaline						
Inj 0.06 mg per ml, 100 ml bag					H 1%	
Inj 0.06 mg per ml, 50 ml syringe					H 1%	
Inj 0.1 mg per ml, 100 ml bag					H 1%	
Inj 0.12 mg per ml, 100 ml bag					H 1%	
Inj 0.12 mg per ml, 100 ml bag					H 1%	
Inj 0.16 mg per ml, 50 ml syringe					H 1%	

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Cardiovascular System

Chemical Name						
Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments	
Noradrenaline						
Inj 1 mg per ml, 100 ml bag				H 1%		
Inj 1 mg per ml, 4 ml ampoule				H 1%		
Pentoxifylline [oxpentifylline]						
Tab 400 mg	112,881	\$83,396	\$0.7388	C H 1%		
Perhexiline maleate						
Tab 100 mg	394,978	\$248,441	\$0.6290	C H 1%		
Pindolol						
<u>Tab 5 mg</u>	139,904	\$13,599	\$0.0972	C H 1%		
<u>Tab 10 mg</u>	170,462	\$26,626	\$0.1562	C H 1%		
<u>Tab 15 mg</u>	79,801	\$18,721	\$0.2346	C H 1%		
Propafenone hydrochloride						
Tab 150 mg	109,698	\$89,733	\$0.8180	C H 1%		
Propranolol						
Oral liq 4 mg per ml	144,070			C H 1%	Units are expressed as 'per ml'	
Tab 10 mg	2,996,292	\$109,365	\$0.0365	C H 1%		
Tab 40 mg	2,898,068	\$134,760	\$0.0465	C H 1%		
Sodium nitroprusside						
Inj 50 mg vial				H 1%		
Sotalol						
Inj 10 mg per ml, 4 ml	75	\$981	\$13.0780	C H 1%		
Tab 80 mg	3,804,458	\$209,245	\$0.0550	C H 1%		
Tab 160 mg	279,886	\$29,388	\$0.1050	C H 1%		
Spirolactone						
<u>Tab 25 mg</u>	6,019,360	\$219,707	\$0.0365	C H 1%		
<u>Tab 100 mg</u>	1,417,213	\$167,231	\$0.1180	C H 1%		
Terazosin hydrochloride						
<u>Tab 1 mg</u>	577,828	\$10,320	\$0.0179	C H 1%		
<u>Tab 2 mg</u>	4,626,712	\$74,351	\$0.0161	C H 1%		
<u>Tab 5 mg</u>	3,347,138	\$81,302	\$0.0243	C H 1%		
Timolol maleate						
Tab 10 mg	96,448	\$10,175	\$0.1055	C H 1%		
Trandolapril						
Cap 1 mg	13,854	\$1,514	\$0.1093	C H 1%		
Cap 2 mg	20,368	\$3,222	\$0.1582	C H 1%		
Verapamil hydrochloride						
Inj 2.5 mg per ml, 2 ml	1,779	\$2,683	\$1.5080	C H 1%		
Tab long-acting 120 mg	1,880,603	\$114,341	\$0.0608	C H 1%		
Tab long-acting 240 mg	1,356,512	\$135,651	\$0.1000	C H 1%		

Dermatologicals

Chemical Name						
Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments	
Benzoyl peroxide						
Gel 2.5%				C H 1%	Not currently listed in the Pharmaceutical Schedule. For this product, PHARMAC would also consider cream or solution presentations. Preference would be for gel or cream over solution presentations	
Gel 5%				C H 1%	Not currently listed in the Pharmaceutical Schedule. For this product, PHARMAC would also consider cream or solution presentations. Preference would be for gel or cream over solution presentations	
Betamethasone valerate with clioquinol						
Crm 0.1% with clioquinol 3%	102,525	\$23,854	\$0.2327	C H 1%		

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Dermatologicals

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
Betamethasone valerate with clioquinol					
Oint 0.1% with clioquinol 3%				C H 1%	Not currently listed in the Pharmaceutical Schedule
Betamethasone valerate with fusidic acid					
Crn 0.1% with fusidic acid 2%	294,360	\$68,489	\$0.2327	C H 1%	Preference for a pack size <30 g
Cetomacrogol with glycerol					
Crn 90% with glycerol 10%, 1,000 ml	5,078,000	\$33,007	\$0.0065	C H 1%	There may be a preference for a sodium lauryl sulphate (SLS)-free presentation. There may be a preference for a pump bottle
Crn 90% with glycerol 10%, 100 g				H 1%	There may be a preference for a sodium lauryl sulphate (SLS)-free presentation. There may be a preference for a pump bottle
Crn 90% with glycerol 10%, 500 ml	11,869,000	\$106,821	\$0.0090	C H 1%	There may be a preference for a sodium lauryl sulphate (SLS)-free presentation. There may be a preference for a pump bottle
Clobetasol propionate					
Crn 0.05% (pack size 30 g or less)	3,563,580	\$380,127	\$0.1067	C H 1%	
Oint 0.05% (pack size 30 g or less)	3,455,730	\$368,623	\$0.1067	C H 1%	
Clobetasone butyrate					
Crn 0.05% (pack size 30 g or less)	231,570	\$41,528	\$0.1793 *	C H 1%	
Crn 0.05% (pack size greater than 30 g)	537,700	\$86,731	\$0.1613 *	C H 1%	
Dimethicone					
Lotn 4% - head lice suffocant				C H 1%	Not currently listed in the Pharmaceutical Schedule
Crn 5%, pump bottle	122,000	\$1,154	\$0.0095	C H 1%	
Econazole nitrate					
Crn 1% (pack size 20 g or less)	26,240	\$1,312	\$0.0500 *	C H 1%	
Hydrocortisone					
Oint (pack size 100 g or less)				H 1%	Not currently listed in the Pharmaceutical Schedule
Crn 1% (pack size greater than 15 g and less than 100 g)	12,489,335	\$468,350	\$0.0375	C H 1%	There may be a preference for a sodium lauryl sulphate (SLS)-free presentation
Crn 1% (pack size greater than 100 g)	5,988,246	\$167,671	\$0.0280	C H 1%	There may be a preference for a sodium lauryl sulphate (SLS)-free presentation
Oint (pack size greater than 100 g)				C H 1%	Not currently listed in the Pharmaceutical Schedule
Hydrogen peroxide					
Crn 1%	566,250	\$323,142	\$0.5707 #	C H 1%	A confidential rebate currently exists
Liquid paraffin with white soft paraffin					
Liquid paraffin 50% with white soft paraffin 50% ointment (pack size 100 g or less)				C H 1%	Not currently listed in the Pharmaceutical Schedule
Liquid paraffin 50% with white soft paraffin 50% ointment (pack size greater than 100 g)				C H 1%	Not currently listed in the Pharmaceutical Schedule
Malathion					
Crn 1%				C H 1%	Not currently listed in the Pharmaceutical Schedule
Lotn 0.5%				C H 1%	Not currently listed in the Pharmaceutical Schedule
Methylprednisolone aceponate					
Crn 0.1%	485,325	\$160,157	\$0.3300	C H 1%	
Oint 0.1%	365,715	\$120,686	\$0.3300	C H 1%	
Mupirocin					
Nasal oint 2% (pack size 5 g or less)				C H 1%	Not currently listed in the Pharmaceutical Schedule. Any listing may be subject to a Special Authority restriction

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Dermatologicals

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
Starch					
Powder				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule
Tretinoin					
<u>Crn 0.5 mg per g</u>	885,250	\$246,100	\$0.2780	C H 1%	
Urea					
<u>Crn 10%</u>	18,423,100	\$303,981	\$0.0165	C H 1%	There may be a preference for a pump bottle presentation
Zinc and castor oil					
Oint BP (pack size greater than 30 g)	16,418,017	\$125,762	\$0.0077	C H 1%	

Extemporaneously Compounded Preparations & Galenicals

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
Coal tar					
<u>Soln BP</u>	185,409	\$11,634	\$0.0628	C H 1%	

Genito Urinary System

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
Clotrimazole					
<u>Vaginal crm 1% with applicators</u>	2,285,843	\$94,702	\$0.0414	C H 1%	
<u>Vaginal crm 2% with applicators</u>	1,492,540	\$164,179	\$0.1100	C H 1%	
Condoms					
51 mm or less (nominal width)	69,153	\$6,417	\$0.0928	C	Preference may be given for suppliers that can supply both dispensing pack packs and loose condom packs. Bid prices should reflect prices for (a) dispensing pack packs and loose condom packs (b) dispensing pack packs only (c) loose condom packs only
52 mm - 54 mm (nominal width)	1,210,844	\$112,366	\$0.0928	C	Preference may be given for suppliers that can supply both dispensing pack packs and loose condom packs. Bid prices should reflect prices for (a) dispensing pack packs and loose condom packs (b) dispensing pack packs only (c) loose condom packs only
55 mm - 58 mm (nominal width)	5,703,891	\$529,321	\$0.0928	C	Preference may be given for suppliers that can supply both dispensing pack packs and loose condom packs. Bid prices should reflect prices for (a) dispensing pack packs and loose condom packs (b) dispensing pack packs only (c) loose condom packs only
59 mm or greater (nominal width)	166,387	\$15,437	\$0.0928	C	Preference may be given for suppliers that can supply both dispensing pack packs and loose condom packs. Bid prices should reflect prices for (a) dispensing pack packs and loose condom packs (b) dispensing pack packs only (c) loose condom packs only
Female condom				C	Not currently listed on the Pharmaceutical Schedule. Any listing may be subject to a Special Authority restriction
Flavoured 54 mm or less (nominal width)	683,189	\$63,400	\$0.0928	C	Preference may be given for suppliers that can supply both dispensing pack packs and loose condom packs. Bid prices should reflect prices for (a) dispensing pack packs and loose condom packs (b) dispensing pack packs only (c) loose condom packs only

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Genito Urinary System

Chemical Name						
Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments	
Condoms						
Flavoured 55 mm or greater (nominal width)	474,430	\$44,027	\$0.0928	C	Preference may be given for suppliers that can supply both dispensing pack packs and loose condom packs. Bid prices should reflect prices for (a) dispensing pack packs and loose condom packs (b) dispensing pack packs only (c) loose condom packs only	
Levonorgestrel						
<u>Tab 1.5 mg</u>	45,900	\$160,650	\$3.5000	C H	1%	
Medical lubricating jelly						
<200 ml				C	Not currently listed in the Pharmaceutical Schedule. Must be non-irritant and compatible with condoms	
Medroxyprogesterone acetate						
<u>Inj 150 mg per ml, 1 ml syringe</u>	144,938	\$1,014,566	\$7.0000	C H	1%	
Nystatin						
Vaginal crm 100,000 u per 5 g with applicator(s)	144,750	\$9,090	\$0.0628	C H	1%	Units and unit subsidy expressed as 'per g'
Oestriol						
Crn 1 mg per g with applicator(s)	2,277,540	\$956,567	\$0.4200	C H	1%	
Pessaries 500 mcg	321,380	\$139,906	\$0.4353	C H	1%	
Oxybutynin						
<u>Oral liq 5 mg per 5 ml</u>	416,423	\$49,696	\$0.1193	C H	1%	
<u>Tab 5 mg</u>	6,196,000	\$138,790	\$0.0224	C H	1%	
Tamsulosin						
<u>Tab 400 mcg</u>	970,396	\$131,100	\$0.1351	C H	1%	

Hormone Preparations - Systemic Excluding Contraceptive Hormones

Chemical Name						
Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments	
Clomiphene citrate						
<u>Tab 50 mg</u>	77,119	\$230,122	\$2.9840	C H	1%	
Danazol						
Cap 100 mg	16,156	\$11,039	\$0.6833	C H	1%	
Cap 200 mg	12,044	\$11,783	\$0.9783	C H	1%	
Desmopressin						
Tab 100 mcg	32,079	\$38,923	\$1.2133	C H	1%	
Tab 200 mcg	12,084	\$37,702	\$3.1200	C H	1%	
Dexamethasone phosphate						
<u>Inj 4 mg per ml, 1 ml</u>	53,595	\$138,274	\$2.5800	C H	1%	
<u>Inj 4 mg per ml, 2 ml</u>	77,080	\$277,178	\$3.5960	C H	1%	
Hydrocortisone						
Oral liq 1 mg per ml				C H	1%	Not currently listed in the Pharmaceutical Schedule
Tab 1 mg				C H	1%	Not currently listed in the Pharmaceutical Schedule
<u>Inj 50 mg per ml, 2 ml</u>	6,355	\$31,711	\$4.9900	C H	1%	
Medroxyprogesterone acetate						
<u>Tab 2.5 mg</u>	384,907	\$39,645	\$0.1030	C H	1%	
<u>Tab 5 mg</u>	591,860	\$77,297	\$0.1306	C H	1%	
<u>Tab 10 mg</u>	1,280,895	\$292,467	\$0.2283	C H	1%	
<u>Tab 100 mg</u>	35,026	\$33,800	\$0.9650	C H	1%	
Oestriol						
Tab 2 mg	240,442	\$56,102	\$0.2333	C H	1%	

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Hormone Preparations - Systemic Excluding Contraceptive Hormones

Chemical Name Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
Progesterone [current access]					
Cap 100 mg	23,069	\$12,688	\$0.5500	C H 1%	PHARMAC would only award a tender for either current access or widened access. PHARMAC reserves the right to amend access.
Progesterone [widened access]					
Cap 100 mg			\$0.5500	C H 1%	PHARMAC would only award a tender for either current access or widened access. PHARMAC reserves the right to amend access.
Testosterone					
Transdermal patch 2.5 mg	132,912	\$177,216	\$1.3333	C H 1%	

Infections

Chemical Name Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
Aciclovir					
<u>Tab dispersible 200 mg</u>	1,111,739	\$79,156	\$0.0712	C H 1%	
<u>Tab dispersible 400 mg</u>	5,801,758	\$619,570	\$0.1068	C H 1%	
<u>Tab dispersible 800 mg</u>	988,308	\$187,492	\$0.1897	C H 1%	
Albendazole					
Tab 200 mg				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule. Any listing may be subject to a Special Authority restriction
Tab 400mg	1,280	\$10,010	\$7.8200	C H 1%	
Amoxicillin					
<u>Cap 250 mg</u>	1,670,478	\$54,057	\$0.0324	C H 1%	
<u>Cap 500 mg</u>	15,596,174	\$653,168	\$0.0419	C H 1%	
Amoxicillin clavulanate					
Grans for oral liq amoxicillin 400 mg with potassium clavulanate 57 mg per 5 ml				@ C H 1%	Additional Stock Pharmaceutical. Not currently listed in the Pharmaceutical Schedule
Grans for oral liq amoxicillin 125 mg with potassium clavulanate 31.25 mg per 5 ml	6,999,616	\$112,694	\$0.0161	@ C H 1%	Additional Stock Pharmaceutical
Grans for oral liq amoxicillin 250 mg with potassium clavulanate 62.5 mg per 5 ml	13,306,037	\$291,402	\$0.0219	@ C H 1%	Additional Stock Pharmaceutical
Amphotericin B					
Inj 50 mg				H 1%	
Artemether with lumefantrine					
Tab 20 mg with lumefantrine 120 mg				H 1%	
Artesunate					
Inj 60 mg				H 1%	
Aztreonam					
Inj 1 g				H 1%	
Cefaclor monohydrate					
<u>Cap 250 mg</u>	4,455,794	\$1,158,506	\$0.2600	C H 1%	
<u>Grans for oral liq 125 mg per 5 ml</u>	9,092,010	\$320,948	\$0.0353	C H 1%	
Cefotaxime					
Inj 500 mg				H 1%	
Ceftriaxone sodium					
<u>Inj 500 mg</u>	4,428	\$6,642	\$1.5000	C H 1%	
<u>Inj 1 g</u>	6,932	\$7,237	\$1.0440	C H 1%	
<u>Inj 2 g</u>				H 1%	
Cephalexin monohydrate					
Cap 250 mg				C H 1%	Not currently listed in the Pharmaceutical Schedule
<u>Cap 500 mg</u>	714,079	\$203,512	\$0.2850	C H 1%	

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Infections						
Chemical Name	Units	Cost	Unit Subsidy	DV	Limit	Comments
Line Item						
Chloroquine phosphate						
Tab 250 mg				H	1%	
Cidofovir						
Inj 375 mg per 5 ml				H	1%	
Ciprofloxacin						
Oral liq				H	1%	Tender will be awarded for either 50 mg per ml or 100 mg per ml
Clindamycin						
<u>Cap hydrochloride 150 mg</u>	804,079	\$291,479	\$0.3625	C H	1%	
<u>Inj phosphate 150 mg per ml, 4 ml</u>	635	\$6,350	\$10.0000	C H	1%	
Clofazimine						
Cap 50 mg	4,389	\$15,429	\$3.5154	C H	1%	
Cycloserine						
Cap 250 mg	3,373	\$43,663	\$12.9450	C H	1%	
Demeclocycline						
Cap 150 mg				H	1%	
Cap 300 mg				H	1%	
Fluconazole						
Inj 2 mg per ml, 50 ml				H	1%	
Inj 2 mg per ml, 100 ml				H	1%	
Flucytosine						
Cap 500 mg				H	1%	
Foscarnet sodium						
Inj 24 mg per ml, 250 ml				H	1%	
Fusidic acid						
Tab 250 mg	40,350	\$116,006	\$2.8750	C H	1%	
Hexamine hippurate						
Tab 1 g	201,834	\$37,137	\$0.1840 *	C H	1%	
Itraconazole						
<u>Cap 100 mg</u>	431,306	\$85,972	\$0.1993	C H	1%	
Oral liq 10 mg per ml	2,850	\$2,694	\$0.9453	C H	1%	
Lamivudine						
Tab 300 mg				C H	1%	Not currently listed in the Pharmaceutical Schedule
<u>Oral liq 10 mg per ml</u>	11,040	\$4,715	\$0.4271	C H	1%	
<u>Tab 150 mg</u>	21,522	\$18,832	\$0.8750	C H	1%	
Lymecycline						
Cap 300 mg				C H	1%	Not currently listed in the Pharmaceutical Schedule. Any listing may be subject to a Special Authority restriction
Mebendazole						
Oral liq 100 mg per 5 ml	33,964	\$4,936	\$0.1453	C H	1%	Units and unit subsidy expressed as 'per ml'
Tab 100 mg	38,878	\$39,186	\$1.0079	C H	1%	
Minocycline hydrochloride						
Cap 100 mg	243,471	\$47,039	\$0.1932 *	C H	1%	PHARMAC may choose to accept one or both presentations of minocycline capsules/tablets
Tab 50 mg	749,772	\$72,353	\$0.0965 *	C H	1%	PHARMAC may choose to accept one or both presentations of minocycline capsules/tablets
Nitazoxanide						
Oral liquid 100 mg per 5 ml				H	1%	
Nitrofurantoin						
Oral liq				C H	1%	Not currently listed in the Pharmaceutical Schedule
<u>sole supply</u>						

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Infections

Chemical Name						
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
Phenoxymethylpenicillin (Penicillin V)						
<u>Grans for oral liq 125 mg per 5 ml</u>	1,446,628	\$23,725	\$0.0164		C H 1%	
<u>Grans for oral liq 250 mg per 5 ml</u>	3,702,921	\$64,431	\$0.0174		C H 1%	
Piperacillin with tazobactam						
Inj 4 g with tazobactam 500 mg					H 1%	
Praziquantel						
Tab 600 mg	684	\$5,816	\$8.5000		C H 1%	
Primaquine phosphate						
Tab 7.5 mg	364	\$761	\$2.0893		C H 1%	
Pyrimethamine						
Tab 25 mg	780	\$576	\$0.7390		C H 1%	
Quinine dihydrochloride						
Inj 600 mg					H 1%	
Quinine sulphate						
Tab 300 mg	1,367,814	\$147,888	\$0.1081		C H 1%	
Rifabutin						
<u>Cap 150 mg</u>	8,270	\$58,769	\$7.1063		C H 1%	
Ritonavir						
Tab 100 mg	144,142	\$208,093	\$1.4437	+	C H 1%	
Sodium stibogluconate						
Inj 100 mg per ml					H 1%	
Spiramycin						
Tab 500 mg					H 1%	
Streptomycin sulphate						
Inj 400 mg per ml, 2.5 ml					H 1%	
Sulphadiazine						
Tab 500 mg	696	\$2,960	\$4.2536		C H 1%	
Tigecycline						
Inj 50 mg vial					H 1%	
Tobramycin						
Powder BP					H 1%	
Inj 100 mg per ml, 5 ml vial					H 1%	
Trimethoprim						
Oral liq					C H 1%	Not currently listed in the Pharmaceutical Schedule
Tab 100 mg					C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule
Trimethoprim with sulphamethoxazole [Co-trimoxazole]						
Inj 16 mg with sulphamethoxazole 80 mg per ml, 5 ml ampoule					H 1%	
Zidovudine [AZT]						
<u>Cap 100 mg</u>	13,796	\$21,004	\$1.5225		C H 1%	
<u>Oral liq 10 mg per ml</u>	10,400	\$1,583	\$0.1523		C H 1%	

Musculoskeletal System

Chemical Name						
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
Baclofen						
Oral liq					C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule
<u>Tab 10 mg</u>	4,361,151	\$167,904	\$0.0385		C H 1%	
Colchicine						
<u>Tab 500 mcg</u>	3,855,682	\$388,653	\$0.1008		C H 1%	

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Musculoskeletal System

Chemical Name					DV	
Line Item	Units	Cost	Unit Subsidy		Limit	Comments
Ibuprofen						
Inj 10 mg per ml, 2 ml					H 1%	
Inj 5 mg per ml, 2 ml					H 1%	
<u>Oral liq 20 mg per ml</u>	41,009,333	\$387,538	\$0.0095		C H 1%	
Mefenamic acid						
Cap 250 mg	406,310	\$10,158	\$0.0250 *		C H 1%	
Neostigmine metisulfate with glycopyrronium bromide						
<u>Inj 2.5 mg with glycopyrronium bromide 0.5 mg per ml, 1 ml</u>					H 1%	
Pancuronium bromide						
Inj 2 mg per ml, 2 ml					H 1%	
Pyridostigmine bromide						
Tab 60 mg	516,425	\$200,889	\$0.3890		C H 1%	
Tab modified-release 180 mg					C H 1%	Not currently listed in the Pharmaceutical Schedule
Risedronate sodium						
Tab 35 mg	26,230	\$26,230	\$1.0000		C H 1%	
Rocuronium bromide						
Inj 10 mg per ml, 5 ml					H 1%	
Tenoxicam						
Inj 20 mg	18	\$179	\$9.9500		C H 1%	
<u>Tab 20 mg</u>	1,401,948	\$213,797	\$0.1525		C H 1%	
Vecuronium						
Inj 4 mg					H 1%	
Inj 10 mg					H 1%	

Nervous System

Chemical Name					DV	
Line Item	Units	Cost	Unit Subsidy		Limit	Comments
Alprazolam						
<u>Tab 250 mcg</u>	460,242	\$23,012	\$0.0500		C H 1%	
<u>Tab 500 mcg</u>	391,285	\$25,434	\$0.0650		C H 1%	
<u>Tab 1 mg</u>	160,812	\$16,081	\$0.1000		C H 1%	
Amisulpride						
<u>Oral liq 100 mg per ml</u>	5,145	\$4,502	\$0.8750		C H 1%	
<u>Tab 100 mg</u>	268,435	\$55,655	\$0.2073		C H 1%	
<u>Tab 200 mg</u>	285,831	\$104,423	\$0.3653		C H 1%	
<u>Tab 400 mg</u>	92,340	\$68,516	\$0.7420		C H 1%	
Aprepitant						
Cap 40 mg				+	H 1%	Not currently listed in the Pharmaceutical Schedule. Any listing may be subject to Special Authority restrictions
Atomoxetine						
Cap 10 mg	41,275	\$157,774	\$3.8225 #		C H 1%	A confidential rebate currently exists
Cap 100 mg	6,693	\$33,252	\$4.9682 #		C H 1%	A confidential rebate currently exists
Cap 18 mg	20,560	\$78,591	\$3.8225 #		C H 1%	A confidential rebate currently exists
Cap 25 mg	52,302	\$199,924	\$3.8225 #		C H 1%	A confidential rebate currently exists
Cap 40 mg	47,410	\$181,225	\$3.8225 #		C H 1%	A confidential rebate currently exists
Cap 60 mg	20,105	\$76,851	\$3.8225 #		C H 1%	A confidential rebate currently exists
Cap 80 mg	10,133	\$50,343	\$4.9682 #		C H 1%	A confidential rebate currently exists
Bupropion hydrochloride						
<u>Tab modified-release 150 mg</u>	2,048,127	\$339,313	\$0.1657 #		C H 1%	A confidential rebate currently exists
Codeine phosphate						
<u>Tab 15 mg</u>	7,612,209	\$361,580	\$0.0475		C H 1%	Bids for products with child-resistant packaging are encouraged

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Nervous System

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
Codeine phosphate					
<u>Tab 30 mg</u>	22,924,214	\$1,329,604	\$0.0580	C H 1%	Bids for products with child-resistant packaging are encouraged
<u>Tab 60 mg</u>	1,900,295	\$237,537	\$0.1250	C H 1%	Bids for products with child-resistant packaging are encouraged
Cyclizine lactate					
Inj 50 mg per ml, 1 ml	60,685	\$181,448	\$2.9900	C H 1%	
Dihydrocodeine tartrate					
<u>Tab long-acting 60 mg</u>	5,236,946	\$1,190,515	\$0.2273	C H 1%	
Droperidol					
Inj 2.5 mg per ml, 1 ml				H 1%	
Inj 5 mg per ml, 2 ml				H 1%	
Duloxetine					
Cap modified-release 30 mg				C H 1%	Not currently listed in the Pharmaceutical Schedule
Cap modified-release 60 mg				C H 1%	Not currently listed in the Pharmaceutical Schedule
Fluoxetine hydrochloride					
<u>Cap 20 mg</u>	22,866,610	\$442,012	\$0.0193	C H 1%	
<u>Tab dispersible 20 mg, scored</u>	1,018,749	\$84,892	\$0.0833	C H 1%	
Haloperidol					
<u>Inj 5 mg per ml, 1 ml</u>	75,474	\$162,646	\$2.1550	C H 1%	
<u>Oral liq 2 mg per ml</u>	74,321	\$17,718	\$0.2384	C H 1%	
<u>Tab 500 mcg</u>	1,289,807	\$80,355	\$0.0623	C H 1%	
<u>Tab 1.5 mg</u>	213,865	\$20,167	\$0.0943	C H 1%	
<u>Tab 5 mg</u>	185,972	\$55,271	\$0.2972	C H 1%	
Haloperidol decanoate					
Inj 100 mg per ml, 1 ml	6,407	\$71,630	\$11.1800	C H 1%	
Inj 50 mg per ml, 1 ml	3,996	\$22,689	\$5.6780	C H 1%	
Hyoscine (Scopolamine)					
<u>Patches, 1.5 mg</u>	23,047	\$137,706	\$5.9750	C H 1%	
Hyoscine hydrobromide					
Inj 400 mcg per ml, 1 ml	13,243	\$123,160	\$9.3000	C H 1%	
Levetiracetam					
Inj 100 mg per ml, 5 ml				H 1%	
Oral liq 100 mg per ml				C H 1%	Not currently listed in the Pharmaceutical Schedule
Tab 1 g				C H 1%	Not currently listed in the Pharmaceutical Schedule.
Tab 250 mg	990,614	\$396,741	\$0.4005	C H 1%	Longer transition periods may apply to this product
Tab 500 mg	2,413,019	\$1,154,630	\$0.4785	C H 1%	Longer transition periods may apply to this product
Tab 750 mg	193,740	\$146,047	\$0.7538	C H 1%	Longer transition periods may apply to this product
Lidocaine [lignocaine] hydrochloride with adrenaline					
Inj 1% with adrenaline 1:100,000, 5 ml				H 1%	
Inj 1% with adrenaline 1:200,000, 20 ml				H 1%	Sterile pack preferred
Inj 2% with adrenaline 1:200,000, 20 ml				H 1%	Sterile pack preferred
Lignocaine hydrochloride					
<u>Pump spray 10%, 50 ml CFC-free</u>				H 1%	
Lorazepam					
Inj 2 mg per ml, 1 ml				H 1%	
Inj 4 mg per ml, 1 ml				H 1%	

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Nervous System						
Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments	
Line Item						
Methadone hydrochloride						
Tab 10 - 20 mg				C H 1%	Not currently listed in the Pharmaceutical Schedule	
Metoclopramide hydrochloride						
Oral liq 5 mg per 5 ml				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule	
Morphine sulphate						
<u>Cap long-acting 10 mg</u>	2,812,837	\$478,182	\$0.1700	C H 1%		
<u>Cap long-acting 30 mg</u>	951,104	\$237,776	\$0.2500	C H 1%		
<u>Cap long-acting 60 mg</u>	400,654	\$216,353	\$0.5400	C H 1%		
<u>Cap long-acting 100 mg</u>	266,716	\$170,165	\$0.6380	C H 1%		
<u>Tab long-acting 10 mg</u>	872,003	\$170,041	\$0.1950	C H 1%		
<u>Tab long-acting 30 mg</u>	339,049	\$101,037	\$0.2980	C H 1%		
<u>Tab long-acting 60 mg</u>	152,043	\$87,425	\$0.5750	C H 1%		
<u>Tab long-acting 100 mg</u>	223,517	\$144,168	\$0.6450	C H 1%		
Morphine tartrate						
<u>Inj 80 mg per ml, 1.5 ml</u>	21,916	\$156,042	\$7.1200	C H 1%		
<u>Inj 80 mg per ml, 5 ml</u>	2,313	\$49,808	\$21.5340	C H 1%		
Naltrexone hydrochloride						
<u>Tab 50 mg</u>	62,750	\$158,966	\$2.5333	C H 1%		
Nortriptyline hydrochloride						
<u>Tab 10 mg</u>	8,583,791	\$343,352	\$0.0400	C H 1%		
<u>Tab 25 mg</u>	8,627,924	\$431,396	\$0.0500	C H 1%		
Ondansetron						
<u>Tab 4 mg</u>	1,424,409	\$156,970	\$0.1102	C H 1%		
<u>Tab 8 mg</u>	387,630	\$47,989	\$0.1238	C H 1%		
Ondansetron hydrochloride						
Inj 2 mg per ml, 2 ml				H 1%		
Inj 2 mg per ml, 4 ml				H 1%		
Oxycodone hydrochloride						
Oral liq 5 mg per 5 ml	1,837,005	\$82,298	\$0.0448	C H 1%		
Paroxetine						
<u>Tab 20 mg</u>	12,496,229	\$599,819	\$0.0480	C H 1%		
Pramipexole hydrochloride						
<u>Tab 250 mcg</u>	181,416	\$13,062	\$0.0720	C H 1%		
<u>Tab 1 mg</u>	67,893	\$16,559	\$0.2439	C H 1%		
Prochlorperazine						
Suppos	13,394	\$63,943	\$4.7740	C H 1%	Units and unit subsidy shown are per 25 mg suppository	
Risperidone [current access]						
Orally-disintegrating tablets 0.5 mg	23,764	\$18,179	\$0.7650	C H 1%	PHARMAC would only award a tender for either current access or widened access. PHARMAC reserves the right to amend access.	
Orally-disintegrating tablets 1 mg	27,932	\$42,736	\$1.5300	C H 1%	PHARMAC would only award a tender for either current access or widened access. PHARMAC reserves the right to amend access.	
Orally-disintegrating tablets 2 mg	54,726	\$167,520	\$3.0611	C H 1%	PHARMAC would only award a tender for either current access or widened access. PHARMAC reserves the right to amend access.	
Risperidone [widened access]						
Orally-disintegrating tablets 0.5 mg			\$0.7650	C H 1%	PHARMAC would only award a tender for either current access or widened access. PHARMAC reserves the right to amend access.	

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Nervous System

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
Risperidone [widened access]					
Orally-disintegrating tablets 1 mg			\$1.5300	C H 1%	PHARMAC would only award a tender for either current access or widened access. PHARMAC reserves the right to amend access.
Orally-disintegrating tablets 2 mg			\$3.0611	C H 1%	PHARMAC would only award a tender for either current access or widened access. PHARMAC reserves the right to amend access.
Ropinirole hydrochloride					
<u>Tab 1 mg</u>	1,063,476	\$56,577	\$0.0532	C H 1%	
<u>Tab 2 mg</u>	513,381	\$39,633	\$0.0772	C H 1%	
<u>Tab 250 mcg</u>	874,270	\$20,633	\$0.0236	C H 1%	
<u>Tab 5 mg</u>	61,249	\$8,869	\$0.1448	C H 1%	
Selegiline hydrochloride					
Tab 5 mg	217,030	\$34,855	\$0.1606	C H 1%	
Sertraline					
<u>Tab 50 mg</u>	3,209,324	\$129,785	\$0.0404	C H 1%	
<u>Tab 100 mg</u>	1,034,633	\$72,197	\$0.0698	C H 1%	
Sumatriptan					
<u>Inj 12 mg per ml, 0.5 ml</u>	44,312	\$305,753	\$6.9000	C H 1%	Price should include autoinjector
Nasal spray				C H 1%	Not currently listed in the Pharmaceutical Schedule
<u>Tab 100 mg</u>	294,484	\$161,377	\$0.5480	C H 1%	
<u>Tab 50 mg</u>	773,669	\$230,553	\$0.2980	C H 1%	
Tetrabenazine					
<u>Tab 25 mg</u>	128,680	\$135,573	\$1.0536	C H 1%	
Tetracaine [amethocaine] hydrochloride					
Gel 4%				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule
Tolcapone					
Tab 100 mg	134,309	\$169,497	\$1.2620	C H 1%	
Trimipramine maleate					
Cap 25 mg				C H 1%	Not currently listed in the Pharmaceutical Schedule
Cap 50 mg				C H 1%	Not currently listed in the Pharmaceutical Schedule

Oncology Agents and Immunosuppressants

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
Anagrelide hydrochloride					
Cap 0.5 mg	47,460			PCT C H 1%	Preference for products where stability data >48 hours post-compounding
Azacitidine					
Inj 100 mg				PCT H 1%	A confidential rebate currently applies. Preference for products where stability data >48 hours post-compounding
Azathioprine					
Inj 50 mg			\$126.0000	C H 1%	
<u>Tab 50 mg</u>	4,077,035	\$538,984	\$0.1322	C H 1%	
Tab 25 mg			\$0.1380	C H 1%	
Bacillus Calmette-Guérin (BCG) vaccine					
<u>Inj containing equal to or greater than 500 million CFU</u>				H 1%	
Capecitabine					
<u>Tab 150 mg</u>	171,532	\$85,766	\$0.5000	C H 1%	
<u>Tab 500 mg</u>	816,439	\$816,439	\$1.0000	C H 1%	
<u>sole supply</u>			23		

#=-rebate *=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Oncology Agents and Immunosuppressants

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
Line Item					
Cyclophosphamide					
Tab 50 mg	180,811	\$285,681	\$1.5800	PCT C H 1%	
Cytarabine					
Inj 100 mg				PCT H 1%	Preference for products where stability data >48 hours post-compounding
Inj 1 g				PCT H 1%	Preference for products where stability data >48 hours post-compounding
Inj 2 g				PCT H 1%	Preference for products where stability data >48 hours post-compounding
Dacarbazine					
Inj 200 mg				PCT H 1%	Preference for products where stability data >48 hours post-compounding
Daunorubicin					
Inj 2 mg per ml, 10 ml				H 1%	Preference for products where stability data >48 hours post-compounding
Liposomal daunorubicin					
Inj 50 mg				PCT H 1%	Not currently listed in the Pharmaceutical Schedule. Preference for products where stability data >48 hours post-compounding
Mercaptopurine					
<u>Tab 50 mg</u>			\$1.9764	PCT C H 1%	
Mesna					
Inj 100 mg per ml, 4 ml				PCT H 1%	Preference for products where stability data >48 hours post-compounding
Inj 100 mg per ml, 10 ml				PCT H 1%	Preference for products where stability data >48 hours post-compounding
Tab 400 mg				PCT H 1%	
Tab 600 mg				PCT H 1%	
Methotrexate					
<u>Inj 25 mg per ml, 2 ml</u>		\$39,020	\$4.0400	PCT C H 1%	Preference for products where stability data >48 hours post-compounding
<u>Inj 25 mg per ml, 20 ml</u>		\$2,025	\$27.7800	PCT C H 1%	Preference for products where stability data >48 hours post-compounding
Inj 7.5 mg prefilled syringe	266	\$4,573	\$17.1900	C H 1%	
Inj 10 mg prefilled syringe	1,979	\$34,138	\$17.2500	C H 1%	
Inj 15 mg prefilled syringe	2,215	\$38,497	\$17.3800	C H 1%	
Inj 20 mg prefilled syringe	4,834	\$84,595	\$17.5000	C H 1%	
Inj 25 mg prefilled syringe	2,161	\$38,098	\$17.6300	C H 1%	
Inj 30 mg prefilled syringe	97	\$1,722	\$17.7500	C H 1%	
Mitomycin C					
<u>Inj 5 mg</u>		\$130,631	\$79.7500	PCT C H 1%	Preference for products where stability data >48 hours post-compounding
Mycophenolate mofetil					
<u>Cap 250 mg</u>	734,782	\$183,696	\$0.2500	C H 1%	
Inj 500 mg				H 1%	Preference for products where stability data >48 hours post-compounding
Powder for oral liq 1 g per 5 ml				H 1%	
<u>Tab 500 mg</u>	1,399,193	\$699,597	\$0.5000	C H 1%	
Pegylated liposomal doxorubicin					
Inj 20 mg				PCT H 1%	Not currently listed on the Pharmaceutical Schedule. Any listing may be subject to a Special Authority restriction
Inj 50 mg				PCT H 1%	Not currently listed on the Pharmaceutical Schedule. Any listing may be subject to a Special Authority restriction

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Oncology Agents and Immunosuppressants

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
Pemetrexed					
Powder for infusion, 100 mg				PCT H 1%	Not currently listed in the Pharmaceutical Schedule. Special Authority restrictions for mesothelioma and non-small cell lung cancer may apply, depending on price. Preference for products where stability data >48 hours post-compounding
Powder for infusion, 500 mg				PCT H 1%	Not currently listed in the Pharmaceutical Schedule. Special Authority restrictions for mesothelioma and non-small cell lung cancer may apply, depending on price. Preference for products where stability data >48 hours post-compounding
Temozolomide					
Cap 5 mg	5,924	\$9,478	\$1.6000	C H 1%	
Cap 20 mg	13,887	\$99,986	\$7.2000	C H 1%	
Cap 100 mg	14,290	\$500,150	\$35.0000	C H 1%	
Cap 250 mg	575	\$47,150	\$82.0000	C H 1%	
Topotecan					
Inj 1 mg				PCT H 1%	Not currently listed in the Pharmaceutical Schedule. Preference for products where stability data >48 hours post-compounding
Inj 4 mg				PCT H 1%	Not currently listed in the Pharmaceutical Schedule. Preference for products where stability data >48 hours post-compounding
Vincristine sulphate					
Inj 1 mg per ml, 1 ml				PCT H 1%	Preference for products where stability data >48 hours post-compounding
Inj 1 mg per ml, 2 ml				PCT H 1%	Preference for products where stability data >48 hours post-compounding

Respiratory System and Allergies

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
Cetirizine hydrochloride					
Tab 10 mg	24,147,278	\$383,942	\$0.0159	C H 1%	
Ipratropium bromide					
Nebuliser soln, 250 mcg per ml, 1 ml	59,917	\$9,766	\$0.1630	C H 1%	
Nebuliser soln, 250 mcg per ml, 2 ml	208,647	\$35,157	\$0.1685	C H 1%	
Loratadine					
Oral liq 1 mg per ml	18,077,089	\$384,138	\$0.0213	C H 1%	
Tab 10 mg	24,527,645	\$318,859	\$0.0130	C H 1%	
Montelukast [current access]					
Tab 10 mg	263,295	\$173,775	\$0.6600 #	C H 1%	PHARMAC would only award a tender for either current access or widened access. PHARMAC reserves the right to amend access. A confidential rebate currently exists. Subsidy and delisting protection until 31 December 2016
Tab 4 mg	68,367	\$45,122	\$0.6600 #	C H 1%	PHARMAC would only award a tender for either current access or widened access. PHARMAC reserves the right to amend access. A confidential rebate currently exists. Subsidy and delisting protection until 31 December 2016
Tab 5 mg	87,464	\$57,726	\$0.6600 #	C H 1%	PHARMAC would only award a tender for either current access or widened access. PHARMAC reserves the right to amend access. A confidential rebate currently exists. Subsidy and delisting protection until 31 December 2016

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Respiratory System and Allergies

Chemical Name						
Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments	
Montelukast [widened access]						
Tab 10 mg			\$0.6600 #	C H 1%	PHARMAC would only award a tender for either current access or widened access. PHARMAC reserves the right to amend access. Rebate currently exists. Subsidy and delisting protection until 31 December 2016.	
Tab 4 mg			\$0.6600 #	C H 1%	PHARMAC would only award a tender for either current access or widened access. PHARMAC reserves the right to amend access. Rebate currently exists. Subsidy and delisting protection until 31 December 2016.	
Tab 5 mg			\$0.6600 #	C H 1%	PHARMAC would only award a tender for either current access or widened access. PHARMAC reserves the right to amend access. Rebate currently exists. Subsidy and delisting protection until 31 December 2016.	
Promethazine hydrochloride						
Inj 25 mg per ml, 2 ml	14,775	\$35,430	\$2.3980	C H 1%		
Salbutamol						
<u>Oral liq 2 mg per 5 ml</u>	762,600	\$10,470	\$0.0137	C H 1%		

Sensory Organs

Chemical Name						
Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments	
Acetazolamide						
Inj 500 mg				H 1%		
Acetic acid with propylene glycol						
Ear drops 2.3% with propylene glycol 2.8%	219,730	\$43,757	\$0.1991	C H 1%	Units and unit subsidy expressed as 'per ml'	
Acetylcholine chloride						
Inj 20 mg vial with diluent				H 1%		
Brinzolamide						
Eye drops 1%	254,370	\$497,039	\$1.9540	C H 1%	For products containing BAK, PHARMAC reserves its right to list a BAK or preservative free product for a restricted market. Units and unit subsidy shown are per ml. There may be a preference for clear dropper bottles with a black tip	
Carbomer						
<u>Ophthalmic gel 0.3%, 0.5 g</u>	22,233	\$6,114	\$0.2750	C H 1%		
Ciprofloxacin						
Ear drops 0.3%				C H 1%	Not currently listed in the Pharmaceutical Schedule. Any listing may be subject to a Special Authority restriction	
Dexamethasone with framycetin and gramicidin						
Ear/eye drops 500 mcg with framycetin sulphate 5 mg and gramicidin 50 mcg per ml	408,792	\$229,946	\$0.5625	C H 1%	There may be a preference for clear dropper bottles with a black tip	
Dorzolamide hydrochloride						
Eye drops 2%	19,420	\$37,947	\$1.9540	C H 1%	For products containing BAK, PHARMAC reserves its right to list a BAK or preservative free product for a restricted market. Units and unit subsidy shown are per ml. There may be a preference for clear dropper bottles with a black tip	
Framycetin sulphate						
Ear/Eye drops 0.5%	33,824	\$17,462	\$0.5163 *	C H 1%	There may be a preference for clear dropper bottles with a black tip	

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Sensory Organs						
Chemical Name	Units	Cost	Unit Subsidy	DV	Limit	Comments
Line Item						
Fusidic acid						
Eye drops 1%	343,825	\$309,443	\$0.9000	C H	1%	For products containing BAK, PHARMAC reserves its right to list a BAK or preservative free product for a restricted market. Units and unit subsidy shown are per ml. There may be a preference for clear dropper bottles with a black tip
Hypromellose						
Eye drops 0.5%	77,460	\$10,328	\$0.1333 *	C H	1%	
Levobunolol						
Eye drops 0.5%	8,565	\$11,991	\$1.4000	C H	1%	For products containing BAK, PHARMAC reserves its right to list a BAK or preservative free product for a restricted market. Units and unit subsidy shown are per ml. There may be a preference for clear dropper bottles with a black tip
Levocabastine						
Eye drops 0.5 mg per ml	147,396	\$320,955	\$2.1775	C H	1%	For products containing BAK, PHARMAC reserves its right to list a BAK or preservative free product for a restricted market. Units and unit subsidy shown are per ml. There may be a preference for clear dropper bottles with a black tip
Natamycin						
Eye drops 5%				C H	1%	Not currently listed in Section B of the Pharmaceutical Schedule. For products containing BAK, PHARMAC reserves its right to list a BAK or preservative free product for a restricted market. May be a preference for clear dropper bottles with a black tip
Polyvinyl alcohol						
Eye drops 1.4%	353,700	\$63,196	\$0.1787	C		For products containing BAK, PHARMAC reserves its right to list a BAK or preservative free product for a restricted market. Units and unit subsidy shown are per ml. There may be a preference for clear dropper bottles with a black tip
Eye drops 3%	172,215	\$43,054	\$0.2500	C		For products containing BAK, PHARMAC reserves its right to list a BAK or preservative free product for a restricted market. Units and unit subsidy shown are per ml. There may be a preference for clear dropper bottles with a black tip
Prednisolone acetate						
Eye drops 0.12%	55,570	\$50,013	\$0.9000	C H	1%	
Eye drops 1%	418,400	\$376,560	\$0.9000	C H	1%	
Sodium hyaluronate [Hyaluronic acid]						
Inj 10 mg per ml, 0.85 ml syringe				H	1%	
Inj 14 mg per ml, 0.55 ml syringe				H	1%	
Inj 14 mg per ml, 0.85 ml syringe				H	1%	
Inj 23 mg per ml, 0.6 ml syringe				H	1%	
Sodium hyaluronate [Hyaluronic acid] with chondroitin sulphate						
Inj 30 mg with chondroitin sulphate 40 mg per ml, 0.75 ml syringe				H	1%	
Timolol						
<u>Eye drops 0.25%, gel forming</u>	42,330	\$55,876	\$1.3200	C H	1%	For products containing BAK, PHARMAC reserves its right to list a BAK or preservative free product for a restricted market. Units and unit subsidy shown are per ml. There may be a preference for clear dropper bottles with a black tip

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Sensory Organs

Chemical Name						
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
Timolol						
<u>Eye drops 0.5%, gel forming</u>	48,883	\$73,910	\$1.5120	C H	1%	For products containing BAK, PHARMAC reserves its right to list a BAK or preservative free product for a restricted market. Units and unit subsidy shown are per ml. There may be a preference for clear dropper bottles with a black tip
Travoprost						
Eye drops 0.004%	101,200	\$789,360	\$7.8000 #	C H	1%	For products containing BAK, PHARMAC reserves its right to list a BAK or preservative free product for a restricted market. Units and unit subsidy shown are per ml. There may be a preference for clear dropper bottles with a black tip